$11.10
-1.21-9.83%
Last update: Nov 6, 4:26 AM
Intellia Therapeutics Inc
NTLANASDAQ
The average analyst price target for Intellia Therapeutics is $24.69, 120.8% above the current price. Of 24 analysts, 15 rate it Buy, 5 Hold and 4 Sell. Targets range from $5 to $65. The latest change came on Oct 6, 2026, when Barclays initiated coverage of Intellia Therapeutics with an Underweight rating and a $8 price target.
Price Target Range — 11 Quarters
Analyst Consensus — 24 Analysts
Rating Trend — Last 9 Months
